EGFR-Activating Mutations Correlate with a Fanconi Anemia–like Cellular Phenotype That Includes PARP Inhibitor Sensitivity
نویسندگان
چکیده
منابع مشابه
EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity.
In patients with lung cancer whose tumors harbor activating mutations in the EGF receptor (EGFR), increased responses to platinum-based chemotherapies are seen compared with wild-type cancers. However, the mechanisms underlying this association have remained elusive. Here, we describe a cellular phenotype of cross-linker sensitivity in a subset of EGFR-mutant lung cancer cell lines that is remi...
متن کاملHypomorphic FANCA mutations correlate with mild mitochondrial and clinical phenotype in Fanconi anemia
Fanconi anemia is a rare disease characterized by congenital malformations, aplastic anemia, and predisposition to cancer. Despite the consolidated role of the Fanconi anemia proteins in DNA repair, their involvement in mitochondrial function is emerging. The purpose of this work was to assess whether the mitochondrial phenotype, independent of genomic integrity, could correlate with patient ph...
متن کاملPredicting PARP inhibitor sensitivity and resistance
A healthy diet rich in fruits and vegetables is an important part of a healthy lifestyle. Whereas epidemiological data sometimes fail to provide proof of this concept, molecular evidence is accumulating that clearly shows both preventive as well as therapeutic effects of compounds from natural origins. in the paper of Guido Kroemer's group about pro-autophagic polyphenols and their inhibitory e...
متن کاملINVITED COMMENTARY Biomarkers of PARP inhibitor sensitivity
The PARP inhibitors represent one of the most exciting recent developments in cancer therapy. Substantial efficacy has been shown with PARP inhibitors in the treatment of hereditary BRCA1/2 related Breast and Ovarian cancer as single agents [1–3] and in combination with temozolomide [4]. Similarly, encouraging activity has been shown in sporadic ovarian cancer with a PARP inhibitor as a single ...
متن کاملLKB1 is a DNA damage response protein that regulates cellular sensitivity to PARP inhibitors
Liver kinase B1 (LKB1) functions as a tumor suppressor encoded by STK11, a gene that mutated in Peutz-Jeghers syndrome and in sporadic cancers. Previous studies showed that LKB1 participates in IR- and ROS-induced DNA damage response (DDR). However, the impact of LKB1 mutations on targeted cancer therapy remains unknown. Herein, we demonstrated that LKB1 formed DNA damage-induced nuclear foci a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer Research
سال: 2013
ISSN: 0008-5472,1538-7445
DOI: 10.1158/0008-5472.can-13-0044